SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is currently trending due to heightened buyout speculation and strong sector momentum, as community members closely watch for potential consolidation activity following recent pharmaceutical acquisitions. Investors are actively debating the company's valuation, recent pipeline strategic shifts, and the high short interest that continues to fuel intense discussion around a possible squeeze or M&A exit.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is currently drawing significant attention as investors monitor its aggressive production ramp-up for F-Series trucks and anticipation surrounding a potential reveals of its next-generation electric vehicle platform. Market participants are closely tracking the company's shift toward energy storage solutions, with the community actively debating the long-term impact of its strategic supply agreements and potential impacts on future quarterly guidance.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Root Inc is currently generating significant community buzz as investors debate the impact of their embedded insurance strategy through partnerships with Hyundai and Carvana, while closely watching for upcoming earnings and potential state rollouts. Discussions are polarized between bulls betting on a data-driven turnaround and a share buyback program, and skeptical traders highlighting concerns over growth stagnation and executive compensation.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc is trending as investors digest a string of strategic partnerships, including a significant rollout with Walmart, while the community heavily debates its potential for a short squeeze amid high short interest and institutional accumulation. Bulls are focused on the stock's role as a scalable, AI-integrated digital healthcare platform, contrasting its long-term infrastructure value against the current price action and the ongoing operational turnaround.

Lionsgate Studios Corp. operates as a standalone, pure-play content company focused on creating, producing, and distributing premium entertainment across multiple formats and platforms. It operates through the following segments: Motion Picture and Television Production. The Motion Picture segment includes the development and production of feature films, acquisition of North American and worldwide distribution rights, North American theatrical, home entertainment, and television distribution of produced and acquired films, as well as the worldwide licensing of distribution rights. The Television Production segment covers the development, production, and worldwide distribution of television content, including series, television movies, mini-series, and non-fiction programming. The company was founded on January 13, 2024 and is headquartered in Vancouver, Canada.

Lionsgate Studios Corp. - Ordinary Shares - New

Lionsgate Studios Corp.

Lionsgate Studios is trending as investors focus on persistent buyout speculation and recent reports that the company has formally engaged an advisor to explore acquisition proposals. While some traders are closely watching the activity of potential suitors like the Bollor Group and Banijay, the community remains actively divided between those betting on a premium M&A exit and others frustrated by the stock's volatility amid denied rumors involving larger streaming giants.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP) is seeing intense community debate, with bulls citing its limited supply and potential DeFi recovery as catalysts, while bears point to persistent price declines and comparisons to competitors like Aave. Investors are closely monitoring potential regulatory developments and volume fluctuations as they weigh whether current levels represent a generational buying opportunity or a deeper correction.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is seeing significant market activity as FDA advisory committee members move forward with favorable votes on expanding the compounding list for popular peptides, providing a potential new growth pillar for the company's telehealth platform. While short interest remains elevated and the stock has faced volatile price action, community members are actively debating the long-term potential of these new healthcare categories against the backdrop of broader market pressures.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors anticipate imminent Phase 3 IZAR-1 clinical trial data, with community discussion intensely focused on potential best-in-class efficacy for sonelokimab in psoriatic arthritis. Market participants are closely watching for a potential data release, which many speculate could trigger a significant re-rating or catalyze acquisition interest from major pharmaceutical players.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick Mining Corp is trending as investors weigh its upcoming North American IPO and strong share buyback program against sector-wide concerns surrounding geopolitical instability in the Middle East and rising commodity costs. The community is actively discussing Barrick's positioning within the broader precious metals and copper supercycle, while evaluating the impact of inflationary pressures on mining margins and the company's long-term production potential.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc - Ordinary Shares - 144A

Nasdaq Inc

Nasdaq Inc. is attracting investor attention as market participants navigate volatility, regulatory shifts, and the high-profile IPO landscape. The community is actively debating the impact of recent exchange rule changes on market structure and liquidity, while monitoring broader tech sector performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Exide sees marginal rise in Q4 net profit

Kolkata: Exide Industries reported a marginal rise in Q4 net profit to Rs 312 crore from Rs 255 crore a year ago, while revenue increased from Rs 4,15.

Best Battery Sector Stocks in India for 2026 Investment Guide

Battery sector stocks in India guide: battery sector growth via electric vehicles, with insights on Exide Industries and HBL Engineering for smart investing decisions.

Brief India: US Semiconductor China Export Restrictions. Game, Set & Now Let's Try MATCH! and more

In this briefing: US Semiconductor China Export Restrictions. Game, Set & Now Let's Try MATCH! Exencial Industry Tidings - 27-04-2026 APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 1. US Semiconductor China Export Restrictions. Game, Set & Now Let's Try MATCH! On April 2, 2026, a bipartisan group of US lawmakers introduced H.R. 8170, the Multilateral Alignment of Technology Controls on Hardware Act, or the MATCH Act. Three weeks later, on April 22, the House Foreign Affairs Committee advanced it in what lawmakers called ”the largest significant export control mark-up in the history of Congress.” If enacted, the immersion DUV ban will deal a serious blow to China's semiconductor ambitions in the medium term. It will also greatly accelerate Chinese efforts to develop their own... 2. Exencial Industry Tidings - 27-04-2026 Revenues of Reliance Consumer Products double to Rs.220 bln in 2025-26 Govt likely to keep prices of fertilisers unchanged, subsidy to remain high India EV market shifts toward mid-priced vehicles as entry segment declines 3.

Brief India: Exencial Industry Tidings - 27-04-2026 and more

In this briefing: Exencial Industry Tidings - 27-04-2026 APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 Primer: Delta Manufacturing (DELTAMAG IN) - Apr 2026 1. Exencial Industry Tidings - 27-04-2026 Revenues of Reliance Consumer Products double to Rs.220 bln in 2025-26 Govt likely to keep prices of fertilisers unchanged, subsidy to remain high India EV market shifts toward mid-priced vehicles as entry segment declines 2. APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear Sino Biopharmaceutical received approval for Benmelstobart plus Anlotinib for alveolar soft part sarcoma in China. Wuxi Biologics announced that three of its manufacturing facilities received GMP certification from South Korea. Astellas Pharma has been granted Priority Review status by the FDA for indication expansion application for Padcev.

Brief India: APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear and more

In this briefing: APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 Primer: Delta Manufacturing (DELTAMAG IN) - Apr 2026 Primer: Zen Technologies (ZEN IN) - Apr 2026 1. APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear Sino Biopharmaceutical received approval for Benmelstobart plus Anlotinib for alveolar soft part sarcoma in China. Wuxi Biologics announced that three of its manufacturing facilities received GMP certification from South Korea. Astellas Pharma has been granted Priority Review status by the FDA for indication expansion application for Padcev. Eisai’s Phase 3 trial evaluating Lenvima in RCC did not meet primary endpoints. Celltrion started patient dosing for three of its novel ADC-based anticancer drug candidates. Cochlear has reduced FY26 underlying net profit guidance to A$290–330M from A$435–460M. 2.

Exide Industries Ltd. engages in the provision of manufacturing storage batteries. It operates through the India and Overseas geographical segment. The company was founded in 1946 and is headquartered in Kolkata, India.

Feed

News

Sentiment

Earnings

Fundamentals

Info

EXIDEIND.NSEExide Industries Ltd.

Latest EXIDEIND.NSE News